Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Links shared publicly online about this topic.

0
total visits

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

View full resource at news-medical.net

Tags: Disease and Condition, Pharma, Biogen Idec, Oncology, News, disease